Trial Profile

Open-label Phase 2 Study of N-803 and PD-L1 t-haNK Combined With Bevacizumab in Subjects With Recurrent or Progressive Glioblastoma

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 15 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary) ; Nogapendekin alfa inbakicept (Primary) ; PD-L1-t-haNK (Primary)
Indications Glioblastoma; Gliosarcoma
Focus Adverse reactions
Sponsors ImmunityBio

Most Recent Events

08 Jan 2025 According to Hoag Memorial Hospital Presbyterian media release, Hoag Family Cancer Institute has also been selected as one of two study sites for this study.
17 Jul 2024 Status changed from not yet recruiting to recruiting.
28 May 2024 Planned initiation date changed from 3 Jun 2024 to 17 Jul 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com